Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 660 participants.

Also called NCT04429503

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 660 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04429503
  • EudraCT 2019-003643-30
Other papers using this trial's data
  • Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial Ophthalmology, 2026-05 DOI, PubMed 41223900
  • Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial Lancet (London, England), 2024-03-23 DOI, PubMed 38461843
  • Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial Japanese journal of ophthalmology, 2026-01 DOI, PubMed 41452566, PMC12948817 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Germany, Hungary, Japan, Puerto Rico, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04429503. Randomized; quadruple masking; primary purpose treatment. Start 2020-06-29 (actual); primary completion 2022-05-30 (actual). Results posted on 2023-11-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Acronym
PHOTON
Condition
Diabetic Macular Edema
Condition
Type 1 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
aflibercept
Intervention (Drug)
High-dose aflibercept
Lead sponsor
Regeneron Pharmaceuticals (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04429503
Content hash
c266333befb41c33c366448805c0a34ac2260fd799939fa3d67bf4347156ee68